Gastrointestinal perforation due to bevacizumab in colorectal cancer

Annals of Surgical Oncology

Volumn 14, Issue 6, 2007, Pages 1860-1869

  Saif, Muhammad Wasif ^a   Elfiky, Aymen ^a   Salem, Ronald R ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Bevacizumab; Colorectal cancer; Gastrointestinal perforation

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

BLEEDING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; CONSTIPATION; DIGESTIVE SYSTEM PERFORATION; DIVERTICULOSIS; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; PEPTIC ULCER; PROTEINURIA; REVIEW; SIGMOIDOSCOPY; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; COLONOSCOPY; HUMANS; INTESTINAL PERFORATION; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RISK FACTORS; SIGMOIDOSCOPY; STOMACH DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249894171     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9337-9     Document Type: Review

References (34)

1. American Cancer Society. Colorectal cancer facts and figures - special edition 2005. Available at: http://www.cancer.org /docroot/STT/content/ STT_1x_Colorectal_Cancer_Facts_and_Figures_-_Special_Edition_2005.asp. Accessed January 28, 2007
2. National Comprehensive Cancer Network. Clinical practice guidelines for oncology: Colon cancer version 2.2006. Available at: http://www.nccn.org /professionals/physician_gls/PDF/colon.pdf. Accessed June 18, 2006
3. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-80
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57
6. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-39
7. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-4
8. Emanuel S, Gruninger RH, Fuentes-Pesquera A, et al. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Mol Pharmacol 2004; 66:635-47
9. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59:3374-8
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42
12. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697-705
13. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: final analysis of the TREE study (abstract 3510). Paper presented at American Society of Clinical Oncology 2006
14. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract 2). Paper presented at American Society of Clinical Oncology 2005
15. Saltz LB, Lenz H, Kindler H, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (abstract 169b). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium 2005
16. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) (abstract 3536). Paper presented at American Society of Clinical Oncology 2006
17. Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) (abstract 3537). Paper presented at American Society of Clinical Oncology 2006
18. Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy (abstract 3535). Paper presented at American Society of Clinical Oncology 2006
19. Kretzschmar A, Cunningham D, Berry S, et al. Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: preliminary results from the First BEATrial (abstract 248). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium 2006
20. Van Cutsem E, Michael M, Berry S, et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC: First BEATrial (abstract 250). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium 2006
21. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502-8
22. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-5
23. Hamilton W, Round A, Sharp D, Peters TJ. Clinical features of colorectal cancer before diagnosis: a population-based case-control study. Br J Cancer 2005; 93:399-405
24. Gatto N, Frucht H, Sundararajan V, et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 2003; 95:230-6
25. Beers MH, Berkow R, eds. Gastrointestinal disorders: acute abdomen and surgical gastroenterology. In: The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck & Co., Inc., 1999; pp 269-275
26. Murray MJ, Gonze MD, Nowak LR, Cobb CF. Serum d(-)-lactate levels as an aid to diagnosing acute intestinal ischemia. Am J Surg 1994; 167:575-8
27. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006; 290:H547-59
28. Betsholtz C, Armulik A. Homeostatic functions of vascular endothelial growth factor in adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290:H509-11
29. Kamba T, Tam BYY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290:H560-76
30. Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996; 27:838-44
31. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69(Suppl 3):25-33
32. Genentech Inc. Avastin prescribing information. June 2006
33. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173-80
34. Berry S, Michael M, Kretzschmar A, et al. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: preliminary results from First BEAT (abstract 245). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium 2005